Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15820751 | 0.77 | — | — | |
| SCHEMBL5559452 | 0.73 | PPARG (0.39) | — | |
| SCHEMBL20462620 | 0.68 | ELANE (0.30) | — | |
| SCHEMBL5559278 | 0.68 | — | — | |
| SCHEMBL10212104 | 0.68 | ELANE (0.35) | — | |
| SCHEMBL5558682 | 0.67 | PPARG (0.37) | — | |
| SCHEMBL10227003 | 0.66 | ELANE (0.34) | — | |
| SCHEMBL21721651 | 0.65 | KDM4E (0.38) | — | |
| SCHEMBL21721276 | 0.64 | ELANE (0.33) | — | |
| SCHEMBL21720105 | 0.64 | ELANE (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919515-B2 | 3-phenylpropionic acid derivatives | ADAMED SP. Z O.O. (PL) | 2011-04-05 | — | — | US | disclosed |
| EP-1833805-B1 | NEW 3-PHENYLPROPIONIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES | ADAMED SP ZOO (PL) | 2010-02-10 | — | — | EP | disclosed |
| US-7312338-B2 | 3-phenylpropionic acid derivatives | ADAMED, SP. Z.O.O. (PL) | 2007-12-25 | — | — | US | disclosed |
| US-20070219259-A1 | NEW 3-PHENYLPROPIONIC ACID DERIVATIVES | ADAMED SP. Z O.O. (PL) | 2007-09-20 | — | — | US | disclosed |
| EP-1833805-A1 | NEW 3-PHENYLPROPIONIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES | Adamed SP. Z O.O. (PL) | 2007-09-19 | — | — | EP | disclosed |
| US-20070088061-A1 | New 3-phenylpropionic acid derivatives | ADAMED, SP. Z.O.O. (PL) | 2007-04-19 | — | — | US | disclosed |
| WO-2006067086-A1 | NEW 3-PHENYLPROPIONIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES | ADAMED SP. Z O.O. (PL) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088061-A1 | New 3-phenylpropionic acid derivatives | PPARA, PPARD, PPARG | TRPV1 603/4885 |
| US-20070219259-A1 | NEW 3-PHENYLPROPIONIC ACID DERIVATIVES | PPARA, PPARD, PPARG | TRPV1 535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.